For research use only. Not for therapeutic Use.
DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer[1].
DA 3003-2 (0.3-30 µM; 48 h) shows antiproliferative activity with an IC50 value of 5 µM in PC-3 cells[1].
DA 3003-2 (5, 10 µM; 24, 1 h) induces cell cycle arrest at G2/M phase and increases the expression of P-tyr15 Cdc2 in PC-3 cells[1].
| Catalog Number | R026155 |
| CAS Number | 383907-47-9 |
| Synonyms | 7-chloro-6-(2-morpholin-4-ylethylamino)quinoline-5,8-dione |
| Molecular Formula | C15H16ClN3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H16ClN3O3/c16-11-13(18-4-5-19-6-8-22-9-7-19)14(20)10-2-1-3-17-12(10)15(11)21/h1-3,18H,4-9H2 |
| InChIKey | LGTBDMBBPVNDSZ-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCNC2=C(C(=O)C3=C(C2=O)C=CC=N3)Cl |
| Reference | [1]. Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp Ther Med. 2010 Jul;1(4):647-650. |
